London, UK 7/19/17— Life science measurement and testing firm LGC has acquired LINK Technologies for an undisclosed amount. Based in Scotland with 21 employees, LINK Technologies supplies specialty reagents for oligonucleotide synthesis. LINK will join LGC’s newly formed Nucleic Acid Chemistry business, part of its Genomics division. The Nucleic Acid Chemistry business also includes the Bioresearch oligonucleotide reagent business and the Prime Synthesis Controlled Pore Glass business. “LINK’s products are a great complement to LGC, providing our customers with an expanded product range, increased supply chain security, improved global logistics and industry leading customer support,” stated Brian Kim, president and managing director of LGC’s Genomics division. 

The purchase furthers LGC’s oligo synthesis business, which has expanded in recent years through the purchase of Bioresearch Technologies (see IBO 4/15/15) and Prime Synthesis (see IBO 11/30/16). LINK Technologies’ offerings include off-the-shelf and custom oligo reagents.